Abstract
Thalidomide and the analogues lenalidomide (CC-5013, Revlimid®) and CC-4047 (Actimid®) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFα and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects. These characteristics have made of them promising drugs for treatment of relapsed, refractory and newly diagnosed MM. It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFα and have, except for myelosuppression, less side effects than Thal. Combination of IMiDs with dexamethasone, bortezomib and with chemotherapeutic agents are tested in numerous trials, which will help in determining the optimal combination and administration schedule of different molecules to take advantage of non-overlapping toxicities and synergisms between those agents.
Keywords: immunomodulatory drugs, multiple myeloma, thalidomide, CC-5013, lenalidomide, CC-4047
Current Pharmaceutical Biotechnology
Title: Immunomodulatory Drugs as a Therapy for Multiple Myeloma
Volume: 7 Issue: 6
Author(s): H. De Raeve and K. Vanderkerken
Affiliation:
Keywords: immunomodulatory drugs, multiple myeloma, thalidomide, CC-5013, lenalidomide, CC-4047
Abstract: Thalidomide and the analogues lenalidomide (CC-5013, Revlimid®) and CC-4047 (Actimid®) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFα and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects. These characteristics have made of them promising drugs for treatment of relapsed, refractory and newly diagnosed MM. It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFα and have, except for myelosuppression, less side effects than Thal. Combination of IMiDs with dexamethasone, bortezomib and with chemotherapeutic agents are tested in numerous trials, which will help in determining the optimal combination and administration schedule of different molecules to take advantage of non-overlapping toxicities and synergisms between those agents.
Export Options
About this article
Cite this article as:
De Raeve H. and Vanderkerken K., Immunomodulatory Drugs as a Therapy for Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116847
DOI https://dx.doi.org/10.2174/138920106779116847 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology
Current Vascular Pharmacology Biologically Active Natural Products of the Genus Callicarpa
Current Bioactive Compounds Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Entry of Oximes into the Brain: A Review
Current Medicinal Chemistry Biological Activities of Natural and Engineered Cyclotides, a Novel Molecular Scaffold for Peptide-Based Therapeutics
Current Molecular Pharmacology Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Novel Artemisinin-Derived Dimers: Synthesis and Evaluation of Anti-cancer Activities
Letters in Drug Design & Discovery Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry New Inhibitors of Glycogen Phosphorylase as Potential Antidiabetic Agents
Current Medicinal Chemistry Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects
Current Neuropharmacology Developing Practical Therapeutic Strategies that Target Protein SUMOylation
Current Drug Targets Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry